2020
Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis
Kahn S, Julian J, Kearon C, Gu C, Cohen D, Magnuson E, Comerota A, Goldhaber S, Jaff M, Razavi M, Kindzelski A, Schneider J, Kim P, Chaer R, Sista A, McLafferty R, Kaufman J, Wible B, Blinder M, Vedantham S, Sichlau M, Vlahos A, Smith S, Thalheimer Q, Singh N, Harting R, Gocke J, Guth S, Shah N, Brady P, Schatz M, Horrow M, Markazi P, Forouzan L, Matalon T, Hertzog D, Goday S, Kennedy M, Kaplan R, Campbell T, Hartman J, Nahum E, Venkat A, Krishnamurthy V, Rectenwald J, Henke P, Eliason J, Willatt J, Escobar G, Samuels S, Katzen B, Benenati J, Powell A, Pena C, Wallach H, Gandhi R, Schneider J, Kim S, Hashemi F, Boyle J, Patel N, Verta M, Leung D, Garcia M, Blatt P, Khatri J, Epstein D, Ryan R, Sweeny T, Stillabower M, Kimbiris G, Raman T, Sierzenski P, Getto L, Dignazio M, Sierzenski P, Horvath M, Gornik H, Bartholomew J, Shishehbor M, Peacock F, Joseph D, Kim S, Mahlay N, Clair D, Lyden S, Kapoor B, McLennon G, Pierce G, Newman J, Spain J, Gill A, Hamilton A, Rizzo A, Park W, Dietzek A, Galin I, Plummer D, Hsu R, Broderick P, Keller A, Sayeed S, Slater D, Lustberg H, Akus J, Sidman R, Dhami M, Kohanski P, Bulgaru A, Dulala R, Burch J, Kapur D, Yang J, Ranson M, Wladis A, Varnagy D, Mekhail T, Winter R, Perez-Izquierdo M, Motew S, Royd-Kranis R, Workman R, Kribbs S, Hogsette G, Moore P, Thomason B, Means W, Bonsall R, Stewart J, Golwya D, Azene E, Bottner W, Bishop W, Clayton D, Gundersen L, Riherd J, Shakhnovich I, Ziegelbein K, Chang T, Sharma K, Allison S, Banovac F, Cohen E, Furlong B, Kessler C, McCullough M, Spies J, Lin J, Kaatz S, Getzen T, Miller J, Schwartz S, Kabbani L, McVinnie D, Rundback J, Manno J, Schwab R, Cole R, Herman K, Singh D, Barkama R, Patel A, Comerota A, Pigott J, Seiwert A, Whalen R, Russell T, Assi Z, Kazanjian S, Yobbagy J, Kaminski B, Kaufman A, Begeman G, DiSalle R, Thakur S, Kim P, Jacquet M, Dykes T, Gerding J, Baker C, Debiasto M, Mittleider D, Higgins G, Amberson S, Pezzuti R, Gallagher T, Schainfeld R, Wicky S, Kalva S, Walker G, Salazar G, Pomerantz B, Patel V, Kabrhel C, Iqbal S, Gangull S, Oklu R, Brannan S, Misra S, Bjarnason H, Ashrani A, Caccavale M, Fleming C, Friese J, Heit J, Kalra M, Macedo T, McBane R, McKusick M, Stockland A, Woodrum D, Wysokinski W, Verma A, Davis A, Chung J, Nicker D, Anderson B, Stein R, Weiss M, Patel P, Rilling W, Tutton S, Hieb R, Hohenwalter E, Colella M, Gosset J, White S, Lewis B, Brown K, Rossi P, Seabrook G, Guimaraes M, Selby J, McGary W, Hannegan C, Robison J, Brothers T, Elliott B, Garg N, Anderson M, Uflacker R, Schonholz C, Raney L, Greenberg C, Kaufman J, Keller F, Kolbeck K, Landry G, Mitchell E, Barton R, DeLoughery T, Kalbfleisch N, Minjarez R, Lakin P, Liem T, Moneta G, Farsad K, Fleischman R, French L, Marques V, Al−Hassani Y, Sawar A, Taylor F, Patel R, Malhotra R, Kim D, Hashemi F, Boyle J, Patel R, Padnick M, Gurley M, Cucher F, Sterrenberg R, Deepthi G, Cumaranatunge G, Bhatla S, Jacobs D, Dolen E, Gamboa P, Dean L, Davis T, Lippert J, Khanna S, Schirf B, Silber J, Wood D, McGraw J, LaPerna L, Willette P, Murphy T, Cerezo J, Dhangana R, Ahn S, Dubel G, Haas R, Jay B, Prince E, Soares G, Klinger J, Lambiase R, Jay G, Tubbs R, Beland M, Hampson C, O'Hara R, Thompson C, Beland M, Frodsham A, Gardiner F, Jaffan A, Keating L, Zafar A, Alicic R, Raabe R, Brower J, McClellan D, Pellow T, Zylak C, Davis J, Reilly M, Symington K, Seibold C, Nachreiner R, Murray D, Murray S, Saha S, Luna G, Hodgson K, McLafferty R, Hood D, Moore C, Griffen D, Hurst D, Lubbers D, Kim K, Warren B, Engel J, Suresh D, VanderWoude E, Razdan R, Hutchins M, Rounsborg T, Midathada M, Moravec D, Tilford J, Kim D, Beckman J, Razavi M, Openshaw K, Flanigan D, Loh C, Dorne H, Chan M, Thomas J, Psaila J, Ringold M, Fisher J, Lipcomb A, Oskin T, Wible B, Coleman B, Elliott D, Gaddis G, Cochran C, Natarajan K, Bick S, Cooke J, Hedderman A, Greist A, Miller L, Martinez B, Flanders V, Underhill M, Hofmann L, Sze D, Kuo W, Louie J, Hwang G, Hovsepian D, Kothary N, Berube C, Schreiber D, Jeffrey B, Schor J, Deitch J, Singh K, Hahn B, Ardolic B, Gupta S, Bashir R, Rao A, Garg M, Patil P, Zack C, Cohen G, Schmieder F, Lakhter V, Sacks D, Guay R, Scott M, Cunningham K, Sigal A, Cescon T, Leasure N, Dhurairaj T, Muck P, Knochel K, Lohr J, Barreau J, Recht M, Bhaskaran J, Brahmamdam R, Draper D, Mehta A, Maher J, Sharafuddin M, Lentz S, Nugent A, Sharp W, Kresowik T, Nicholson R, Sun S, Youness F, Pascarella L, Ray C, Knuttinen M, Bui J, Gaba R, Dobiesz V, Shamim E, Nimmagadda S, Peace D, Zain A, Palumto A, Haskal Z, Hirshon J, Richard H, Verceles A, Wong-You-Chong J, Othee B, Patel R, Iliescu B, Williams D, Gemmete J, Krishnamurthy V, Cwikiel W, Cho K, Schields J, Vellody R, Novelli P, Dasika N, Wakefield T, Rectenwald J, Henke P, Desmond J, Froehlich J, Khaja M, Hunter D, Golzarian J, Cressman E, Dotta Y, Schmiechen N, Marek J, Garcia D, Tawil I, Langsfeld M, Moll S, Mauro M, Stavas J, Burke C, Dixon R, Yu H, Keagy B, Kim K, Kasthuri R, Key N, Chaer R, Makaroun M, Rhee R, Cho J, Baril D, Marone L, Hseih M, Feterik K, Smith R, Jeyabalan G, Rogers J, Vinik R, Kinikini D, Kraiss L, Mueller M, Pendleton R, Rondina M, Sarfati M, Wanner N, Johnson S, Hopkins C, Ihnat D, Angle J, Matsumoto A, Harthun N, Turba U, Saad W, Uthlaut B, Nannapaneni S, Ling D, Sabri S, Kern J, Macik B, Hoke G, Park A, Stone J, Sneed B, Syverud S, Davidson K, Sharma A, Haskal Z, Wilkins L, Black C, Asay M, Hatch D, Smilanich R, Patten C, Brown S, Nielsen R, Alward W, Collins J, Nokes M, Geary R, Edwards M, Godshall C, Levy P, Winokur R, Sista A, Madoff D, Lee K, Pua B, DeSancho M, Milizia R, Gao J, Goday S, Kennedy M, Kaplan R, Campbell T, McLean G, Hartman J, Nahum E, Khalid S, Vedantham S, Lewis L, Saad N, Thoelke M, Pallow R, Klein S, Sicard G, Cohen D, Comerota A, Gornik H, Jaff M, Julian J, Kahn S, Kearon C, Kee S, Kindzelski A, Lewis L, Magnuson E, Razavi M, Murphy T, Vedantham S. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2020, 8: 8-23.e18. PMID: 31843251, PMCID: PMC7681916, DOI: 10.1016/j.jvsv.2019.03.023.Peer-Reviewed Original ResearchConceptsPharmacomechanical catheter-directed thrombolysisProximal deep venous thrombosisDeep venous thrombosisQuality of lifeDisease-specific QOLIliofemoral deep venous thrombosisCatheter-directed thrombolysisPhysical component summaryVenous thrombosisPCDT groupChange scoresDVT patientsQOL measuresForm Health Survey Physical Component SummaryExtent of DVTLong-term QOLAssessor-blinded randomized trialGeneral QOL measuresVenous Insufficiency EpidemiologicalAcute venous thrombosisDisease-specific QOL measuresGreater improvementThrombolysis trialsCommon femoralComponent summary
2014
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients
2013
Percutaneous Intraportal Application of Adipose Tissue–derived Mesenchymal Stem Cells Using a Balloon Occlusion Catheter in a Porcine Model of Liver Fibrosis
Avritscher R, Abdelsalam ME, Javadi S, Ensor J, Wallace MJ, Alt E, Madoff DC, Vykoukal JV. Percutaneous Intraportal Application of Adipose Tissue–derived Mesenchymal Stem Cells Using a Balloon Occlusion Catheter in a Porcine Model of Liver Fibrosis. Journal Of Vascular And Interventional Radiology 2013, 24: 1871-1878. PMID: 24144538, DOI: 10.1016/j.jvir.2013.08.022.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAnimalsBalloon OcclusionBiomarkersBiopsyCell TrackingCells, CulturedEndovascular ProceduresEquipment DesignEthanolEthiodized OilGreen Fluorescent ProteinsHepatic VeinsLiverLiver Cirrhosis, ExperimentalMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsSus scrofaTime FactorsTransfectionVascular Access DevicesVenous PressureConceptsHepatic venous pressure gradientBalloon occlusion catheterOcclusion catheterMesenchymal stem cellsLiver fibrosisLarge animal modelIntraportal applicationEndovascular approachPortal veinAdipose tissueAnimal modelsExperimental animalsPercutaneous endovascular approachVenous pressure gradientTranscatheter arterial embolizationNovel endovascular approachStem cellsPortal hypertensionVascular complicationsArterial embolizationLiver injuryLiver damageBiopsy specimensSham injectionBalloon inflation
2011
Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation
Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transplantation 2011, 17: s117-s127. PMID: 21584926, DOI: 10.1002/lt.22334.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, HepatocellularDecision Support TechniquesDiagnostic ImagingEvidence-Based MedicineHealth Status IndicatorsHumansLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalNeoplasm StagingPatient SelectionPractice Guidelines as TopicPredictive Value of TestsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeWaiting ListsDevelopment of a Large Animal Model of Cirrhosis and Portal Hypertension Using Hepatic Transarterial Embolization: A Study in Swine
Avritscher R, Wright KC, Javadi S, Uthamanthil R, Gupta S, Gagea M, Bassett RL, Murthy R, Wallace MJ, Madoff DC. Development of a Large Animal Model of Cirrhosis and Portal Hypertension Using Hepatic Transarterial Embolization: A Study in Swine. Journal Of Vascular And Interventional Radiology 2011, 22: 1329-1334. PMID: 21802316, DOI: 10.1016/j.jvir.2011.04.016.Peer-Reviewed Original ResearchHigh Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvival
2008
Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization
Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization. Journal Of Vascular And Interventional Radiology 2008, 19: 145-151. PMID: 18192482, DOI: 10.1016/j.jvir.2007.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBrachytherapyCarcinoma, NeuroendocrineChemoembolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMicrospheresMiddle AgedRetrospective StudiesTime FactorsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNeuroendocrine hepatic metastasesHepatic metastasesEmbolization proceduresRadiation-induced liver diseaseYttrium-90 resin microspheresMetastatic neuroendocrine carcinomaCohort of patientsHepatic arterial embolizationTime of diagnosisReasonable therapeutic optionMedian survival timeHepatic artery radioembolizationHepatic progressionDisease stabilizationArterial embolizationPartial responseProgressive diseaseMedian ageLiver diseaseTherapeutic optionsStudy criteriaMicrosphere infusionNeuroendocrine carcinomaSurvival timeMicrosphere radioembolization